{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T17:22:09Z","timestamp":1764350529176,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40123-020-00229-x","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T09:03:02Z","timestamp":1579251782000},"page":"115-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Ocular and Systemic Pharmacokinetics of Brimonidine and Timolol After Topical Administration in Rabbits: Comparison Between Fixed-Combination and Single Drugs"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1911-971X","authenticated-orcid":false,"given":"Gen","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Kunikane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Shinno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiko","family":"Kozai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"issue":"18","key":"229_CR1","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901\u201311.","journal-title":"JAMA"},{"key":"229_CR2","unstructured":"The Japan Glaucoma Society Guidelines for Glaucoma (4th edition). Nihon Ganka Gakkai Zasshi. 2019;122:5\u201353."},{"issue":"6","key":"229_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701\u201313.","journal-title":"Arch Ophthalmol"},{"key":"229_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ajo.2016.12.002","volume":"176","author":"HS Barnebey","year":"2017","unstructured":"Barnebey HS, Robin AL. Adherence to Fixed-combination versus unfixed travoprost 0.004%\/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017;176:61\u20139.","journal-title":"Am J Ophthalmol"},{"key":"229_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/eye.2000.197","volume":"14","author":"AG Konstas","year":"2000","unstructured":"Konstas AG, Maskaleris G, Gratsonidis S, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye. 2000;14:752\u20136.","journal-title":"Eye."},{"issue":"6","key":"229_CR6","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","volume":"112","author":"CM Olthoff","year":"2005","unstructured":"Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953\u201361.","journal-title":"Ophthalmology"},{"issue":"5","key":"229_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ophtha.2004.12.026","volume":"112","author":"AL Robin","year":"2005","unstructured":"Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112(5):863\u20138.","journal-title":"Ophthalmology"},{"issue":"7","key":"229_CR8","first-page":"907","volume":"16","author":"H Abe","year":"1999","unstructured":"Abe H. Improving compliance with medical treatment of glaucoma. J Eye. 1999;16(7):907\u201312.","journal-title":"J Eye."},{"issue":"11","key":"229_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1248\/yakushi.121.799","volume":"121","author":"H Ikeda","year":"2001","unstructured":"Ikeda H, Sato M, Tsukamoto H, et al. Evaluation and multivariate statistical analysis of factors influencing patient adherence to ophthalmic solutions. Yakugaku Zasshi. 2001;121(11):799\u2013806.","journal-title":"Yakugaku Zasshi"},{"issue":"Suppl","key":"229_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/0039-6257(83)90142-X","volume":"28","author":"TJ Zimmerman","year":"1983","unstructured":"Zimmerman TJ, Zalta AH. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol. 1983;28(Suppl):252\u20138.","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"229_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2165\/00002512-199812030-00005","volume":"12","author":"JC Adkins","year":"1998","unstructured":"Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging. 1998;12(3):225\u201341.","journal-title":"Drugs Aging"},{"key":"229_CR12","first-page":"1409","volume-title":"The glaucomas","author":"TW Mittag","year":"1996","unstructured":"Mittag TW. Adrenergic and dopaminergic drugs in glaucoma. In: Ritch R, Schields MB, Krupin T, editors. The glaucomas. Maryland Heights: Mosby; 1996. p. 1409\u201324."},{"issue":"3","key":"229_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2147\/OPTH.S3840","volume":"2","author":"AJ Lee","year":"2008","unstructured":"Lee AJ, McCluskey P. Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure. Clin Ophthalmol. 2008;2(3):545\u201355.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"229_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","volume":"151","author":"T Krupin","year":"2011","unstructured":"Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol. 2011;151(4):671\u201381.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"229_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/IJG.0000000000001285","volume":"28","author":"Y Yokoyama","year":"2019","unstructured":"Yokoyama Y, Kawasaki R, Takahashi H, et al. Effects of brimonidine and timolol on the progression of visual field defects in open-angle glaucoma: a single-center randomized trial. J Glaucoma. 2019;28(7):575\u201383.","journal-title":"J Glaucoma"},{"issue":"4","key":"229_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/archophthalmol.2009.9","volume":"127","author":"M Saylor","year":"2009","unstructured":"Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol. 2009;127(4):402\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"229_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/jps.2600630304","volume":"63","author":"SS Chrai","year":"1974","unstructured":"Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63(3):333\u20138.","journal-title":"J Pharm Sci"},{"issue":"12","key":"229_CR18","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/jps.2600651230","volume":"65","author":"JW Sieg","year":"1976","unstructured":"Sieg JW, Robinson JR. Mechanistic studies on transcorneal permeation of pilocarpine. J Pharm Sci. 1976;65(12):1816\u201322.","journal-title":"J Pharm Sci"},{"issue":"1","key":"229_CR19","first-page":"110","volume":"26","author":"GM Grass","year":"1985","unstructured":"Grass GM, Wood RW, Robinson JR. Effects of calcium chelating agents on corneal permeability. Invest Ophthalmol Vis Sci. 1985;26(1):110\u20133.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"229_CR20","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/jps.2600620712","volume":"62","author":"SS Chrai","year":"1973","unstructured":"Chrai SS, Patton TF, Mehta A, Robinson JR. Lacrimal and instilled fluid dynamics in rabbit eyes. J Pharm Sci. 1973;62(7):1112\u201321.","journal-title":"J Pharm Sci"},{"issue":"3","key":"229_CR21","first-page":"871","volume":"246","author":"VH Lee","year":"1988","unstructured":"Lee VH, Chien DS, Sasaki H. Ocular ketone reductase distribution and its role in the metabolism of ocularly applied levobunolol in the pigmented rabbit. J Pharmacol Exp Ther. 1988;246(3):871\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"229_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/0014-4835(92)90030-V","volume":"54","author":"SK Podder","year":"1992","unstructured":"Podder SK, Moy KC, Lee VH. Improving the safety of topically applied timolol in the pigmented rabbit through manipulation of formulation composition. Exp Eye Res. 1992;54(5):747\u201357.","journal-title":"Exp Eye Res"},{"issue":"4","key":"229_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1089\/10807680260218498","volume":"18","author":"AA Acheampong","year":"2002","unstructured":"Acheampong AA, Small D, Baumgarten V, Welty D, Tang-Liu D. Formulation effects on ocular absorption of brimonidine in rabbit eyes. J Ocul Pharmacol Ther. 2002;18(4):325\u201337.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"229_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/1080768041725326","volume":"20","author":"JQ Dong","year":"2004","unstructured":"Dong JQ, Babusis DM, Welty DF, Acheampong AA, Tang-Liu D, Whitcup SM. Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther. 2004;20(4):285\u201392.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"7","key":"229_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/IJG.0b013e318162257f","volume":"17","author":"LB Cantor","year":"2008","unstructured":"Cantor LB, WuDunn D, Catoira-Boyle Y, Yung CW. Absorption of brimonidine 0.1% and 0.15% ophthalmic solutions in the aqueous humor of cataract patients. J Glaucoma. 2008;17(7):529\u201334.","journal-title":"J Glaucoma"},{"issue":"9","key":"229_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.2042-7158.1995.tb06726.x","volume":"47","author":"H Sasaki","year":"1995","unstructured":"Sasaki H, Nagano T, Yamamura K, Nishida K, Nakamura J. Ophthalmic preservatives as absorption promoters for ocular drug delivery. J Pharm Pharmacol. 1995;47(9):703\u20137.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"229_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0378-5173(96)04663-7","volume":"142","author":"MF Saettone","year":"1996","unstructured":"Saettone MF, Chetoni P, Cerbai R, Mazzanti G, Braghiroli L. Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four \u03b2-blockers, and in vitro\/in vivo toxic activity. Int J Pharm. 1996;142(1):103\u201313.","journal-title":"Int J Pharm"},{"issue":"9","key":"229_CR28","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1023\/A:1015810619869","volume":"8","author":"P Ashton","year":"1991","unstructured":"Ashton P, Podder SK, Lee VH. Formulation influence on conjunctival penetration of four beta blockers in the pigmented rabbit: a comparison with corneal penetration. Pharm Res. 1991;8(9):1166\u201374.","journal-title":"Pharm Res"},{"issue":"10","key":"229_CR29","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/eye.2013.146","volume":"27","author":"J Nirmal","year":"2013","unstructured":"Nirmal J, Singh SB, Biswas NR, et al. Potential pharmacokinetic role of organic cation transporters in modulating the transcorneal penetration of its substrates administered topically. Eye. 2013;27(10):1196\u2013203.","journal-title":"Eye"},{"issue":"10","key":"229_CR30","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1248\/bpb.29.2143","volume":"29","author":"K Sakanaka","year":"2006","unstructured":"Sakanaka K, Kawazu K, Nishida K, et al. Transport of timolol and tilisolol in rabbit corneal epithelium. Biol Pharm Bull. 2006;29(10):2143\u20137.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"229_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/jop.1989.5.127","volume":"5","author":"A Urtti","year":"1989","unstructured":"Urtti A, Kyyr\u00f6nen K. Ophthalmic epinephrine, phenylephrine, and pilocarpine affect the systemic absorption of ocularly applied timolol. J Ocul Pharmacol. 1989;5(2):127\u201332.","journal-title":"J Ocul Pharmacol"},{"issue":"3","key":"229_CR32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/OPX.0000000000001182","volume":"95","author":"E McLaurin","year":"2018","unstructured":"McLaurin E, Cavet ME, Gomes PJ, Ciolino JB. Brimonidine ophthalmic solution 0.025% for reduction of ocular redness: a randomized clinical trial. Optom Vis Sci. 2018;95(3):264\u201371.","journal-title":"Optom Vis Sci."},{"issue":"5","key":"229_CR33","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1089\/jop.2015.0003","volume":"31","author":"Y Takamura","year":"2015","unstructured":"Takamura Y, Tomomatsu T, Matsumura T, et al. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans. J Ocul Pharmacol Ther. 2015;31(5):282\u20135.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"Suppl 1","key":"229_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0039-6257(96)82027-3","volume":"41","author":"J Burke","year":"1996","unstructured":"Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996;41(Suppl 1):9\u201318.","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"229_CR35","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1080\/02713683.2016.1238941","volume":"42","author":"K Shinno","year":"2017","unstructured":"Shinno K, Kurokawa K, Kozai S, Kawamura A, Inada K, Tokushige H. The relationship of brimonidine concentration in vitreous body to the free concentration in retina\/choroid following topical administration in pigmented rabbits. Curr Eye Res. 2017;42(5):748\u201353.","journal-title":"Curr Eye Res"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-020-00229-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-020-00229-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-020-00229-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T15:31:15Z","timestamp":1652283075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-020-00229-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["229"],"URL":"https:\/\/doi.org\/10.1007\/s40123-020-00229-x","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"type":"print","value":"2193-8245"},{"type":"electronic","value":"2193-6528"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"4 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The license text was incorrectly structured. The article has been corrected.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}